Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $376656.0.

  • InMed Pharmaceuticals' Accumulated Expenses rose 1168.91% to $376656.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $376656.0, marking a year-over-year increase of 1168.91%. This contributed to the annual value of $490405.0 for FY2025, which is 43.56% up from last year.
  • As of Q4 2025, InMed Pharmaceuticals' Accumulated Expenses stood at $376656.0, which was up 1168.91% from $274250.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Accumulated Expenses registered a high of $839638.0 during Q2 2022, and its lowest value of $101775.0 during Q4 2023.
  • Over the past 5 years, InMed Pharmaceuticals' median Accumulated Expenses value was $353465.0 (recorded in 2024), while the average stood at $361903.7.
  • Per our database at Business Quant, InMed Pharmaceuticals' Accumulated Expenses plummeted by 3541.2% in 2023 and then skyrocketed by 23135.45% in 2024.
  • InMed Pharmaceuticals' Accumulated Expenses (Quarter) stood at $382114.0 in 2021, then surged by 119.73% to $839638.0 in 2022, then tumbled by 87.88% to $101775.0 in 2023, then surged by 231.35% to $337236.0 in 2024, then grew by 11.69% to $376656.0 in 2025.
  • Its Accumulated Expenses was $376656.0 in Q4 2025, compared to $274250.0 in Q3 2025 and $490405.0 in Q2 2025.